CADL Overview

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is18.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Candel Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Candel Therapeutics Inc. EPS for the last quarter amounts to -0.14 USD, decreased -207.69

Candel Therapeutics Inc (CADL) has 55 emplpoyees as of May 17 2026.

Today CADL has the market capitalization of 642.58M USD.